live, attenuated herpes zoster vaccine
Trade name: varilrix
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine are more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of the disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin. Another vaccine, known as zoster vaccine, is used to prevent diseases caused by the same virus – the varicella zoster virus. — Wikipedia
Clinical trial activity
26 trials · 4 clinical orgs · 0 marketing orgs
Earliest trial started Feb 1, 2007 (NCT00434577)
Timeline
Indications
Approved for
Mechanism of action
- Human herpesvirus 3Immunity, active
Human herpesvirus 3 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaVaricella vaccine ↗
Also known as
- gsk 1437173
- gsk1437173a
- gsk 1437173a
- gsk208133
- live attenuated chicken pox vaccine
- varilrix
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03314103 | Phase 3 | Oct 6, 2017 | Government of China |
| NCT02979639 | Phase 3 | Jan 16, 2017 | GlaxoSmithKline |
| NCT02723773 | Phase 3 | Apr 16, 2016 | GlaxoSmithKline |
| NCT02735915 | Phase 3 | Apr 11, 2016 | GlaxoSmithKline |
| NCT02690207 | Phase 3 | Mar 16, 2016 | GlaxoSmithKline |
| NCT02581410 | Phase 3 | Dec 1, 2015 | GlaxoSmithKline |
| NCT02570126 | Phase 3 | Nov 1, 2015 | GlaxoSmithKline |
| NCT02383797 | Phase 4 | Feb 1, 2015 | University of Helsinki |
| NCT02075515 | Phase 3 | Aug 13, 2014 | GlaxoSmithKline |
| NCT02058589 | Phase 3 | Mar 20, 2014 | GlaxoSmithKline |
| NCT02045836 | Phase 3 | Mar 1, 2014 | GlaxoSmithKline |
| NCT02052596 | Phase 3 | Feb 7, 2014 | GlaxoSmithKline |
| NCT01954251 | Phase 3 | Oct 1, 2013 | GlaxoSmithKline |
| NCT01777321 | Phase 3 | Jun 17, 2013 | GlaxoSmithKline |
| NCT01827839 | Phase 3 | Jun 10, 2013 | GlaxoSmithKline |
| NCT01798056 | Phase 3 | Mar 1, 2013 | GlaxoSmithKline |
| NCT01767467 | Phase 3 | Mar 1, 2013 | GlaxoSmithKline |
| NCT01751165 | Phase 3 | Mar 1, 2013 | GlaxoSmithKline |
| NCT01610414 | Phase 3 | Jul 13, 2012 | GlaxoSmithKline |
| NCT01439360 | Phase 3 | Oct 1, 2011 | GlaxoSmithKline |
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 23 | 23 | 3 | 2007 |
| Cairo University | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Government of China | Government | 1 | 1 | 1 | 2017 |
| University of Helsinki | Academic/Hospital | 1 | 1 | 1 | 2015 |